Astralis' Psoraxine fails Phase II

ASTR's Psoraxine missed the primary endpoint of PASI score improvements in a double-blind, placebo-controlled, U.S. Phase II trial in 120 patients with moderate to severe psoriasis. ASTR said it will ...